9-Year-Old Boy From Indiana Starts Spinraza Treatment


Alexander Davis is a nine-year-old boy from Tipton, Indiana who is embarking on a new journey in his treatment for spinal muscular atrophy (SMA). Alexander was diagnosed with SMA type 2 at the age of one and has just received his first injection of the newly FDA-approved drug, Spinraza (nusinersen).

MORE: SMA Stories – Meet Stella Bartlett

According to a report on fox59.com, his parents, Anastasia and Sean, were told by doctors that Alexander would never be able to walk and that there were no treatments available to alter the course of his disease. The approval of Spinraza offers the Davis family and hundreds of other families real hope that progress can be made and that their children’s condition can be improved.

You can track Alexander’s progress with Spinraza treatment by following the family’s Facebook page: Hakuna Matata for Alexander.

MORE: Canadian families still waiting for Spinraza approval.

SMA News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?


  1. Verónica Tapia García says:

    This is a great wonderfull news!!! I have a child whit SMA 3, she is 10 years old. We live in Quito – Ecuador, and we are very interested in receive the treatment. PLEASE HELP MY LITTLE GIRL, TOO!!!!!!!!!!!

Leave a Comment

Your email address will not be published. Required fields are marked *